Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at La Jolla, California and other locations
Dates
study started
completion around

Description

Summary

The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.

Official Title

A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation

Keywords

Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation, KRAS Mutation, NRAS Mutation, First-Line, Colorectal Neoplasms, Bevacizumab, Onvansertib, FOLFIRI, FOLFOX

Eligibility

Locations

  • UC San Diego Moores Cancer Center accepting new patients
    La Jolla California 92037 United States
  • Sharp Memorial Hospital accepting new patients
    San Diego California 92123 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Cardiff Oncology
ID
NCT06106308
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 90 study participants
Last Updated